Company Description
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.
The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors.
Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
In addition, the company’s development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma.
It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib.
Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.
Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 85 |
| CEO | Nadim Ahmed |
Contact Details
Address: One Main Street, Suite 1350 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 410 4650 |
| Website | cullinantherapeutics.com |
Stock Details
| Ticker Symbol | CGEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $21.00 |
| CIK Code | 0001789972 |
| CUSIP Number | 230031106 |
| ISIN Number | US2300311063 |
| Employer ID | 81-3867811 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nadim Ahmed | President, Chief Executive Officer and Director |
| Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor and Chairman of Scientific Advisory Board |
| Mary Kay Fenton CPA | Chief Financial Officer |
| Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer |
| Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Steve Andre | Chief Human Resources Officer |
| Dr. Corinne Savill Ph.D. | Chief Business Officer |
| Rose Weldon | Senior Vice President of Corporate Affairs |
| Kevin A. Johnston | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | SCHEDULE 13G/A | Filing |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | 8-K | Current Report |